Quince Therapeutics (QNCX) said late Tuesday that the enrollment in its phase 3 clinical trial of the neurological effects of eDSP system on Ataxia-Telangiectasia patients has exceeded 75%.
EDSP is comprised of dexamethasone sodium phosphate encapsulated in a patient's own red blood cells.
A total of 76 participants have been enrolled, including 65 participants in the six- to nine-year-old primary analysis population and 11 participants aged 10 years or above, the company said.
The company said it plans to submit a new drug application to the US Food and Drug Administration in H2 2026, subject to a positive outcome of the trial.
The company said it received the FDA's fast track designation for eDSP system for the treatment of patients with Ataxia-Telangiectasia, a rare neurodegenerative disease.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。